Amfetamine extended-release (liquid suspension)- Neos Therapeutics

Drug Profile

Amfetamine extended-release (liquid suspension)- Neos Therapeutics

Alternative Names: Amphetamine XR-liquid suspension; Amphetamine XR-suspension - Neos Therapeutics; Extended release amphetamine liquid suspension - Neos Therapeutics; NT-0201

Latest Information Update: 19 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neos Therapeutics
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Attention-deficit hyperactivity disorder

Most Recent Events

  • 19 May 2017 Chemical structure information added
  • 15 Mar 2017 Neos Therapeutics has patent protection for methods of preparation of amfetamine extended release in USA until 2025, 2029 and 2031
  • 14 Mar 2017 FDA assigns PDUFA action date of 15/09/2017 for amfetamine extended release for Attention-deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top